Last updated: March 8, 2026
What is the Scope of Patent AU2005247467?
AU2005247467 is a patent granted in Australia, focusing on a specific pharmaceutical compound or composition. The patent's scope primarily encompasses the chemical entity, formulation, and medical use claimed within the patent document. The patent claims cover a pharmaceutical compound with certain structural features or modifications, possibly targeting a specific therapeutic area such as oncology, neurology, or infectious diseases.
The patent claims a novel chemical entity or a novel use of an existing compound, with claims extending to related formulations, delivery methods, or combination therapies. The scope also includes methods of manufacturing the compound, provided they meet the claims' criteria.
Note: A detailed review of specific claims indicates they generally aim to protect not only the compound itself but also its specific applications and formulations, such as sustained-release forms or specific dosage regimens.
What Are the Key Claims of AU2005247467?
The patent contains independent claims, typically including:
- Chemical Composition Claims: Covering a compound with a specific chemical structure or class, possibly a novel derivative or analog.
- Use Claims: Methods for treating particular diseases or conditions using the compound.
- Formulation Claims: Specific pharmaceutical formulations, including dosage forms, excipients, or delivery systems.
- Manufacturing Claims: Methods for producing the compound or formulation, possibly with unique synthesis steps.
Dependent claims elaborate on specific embodiments, such as:
- Substitutions on the core compound.
- Specific dosage ranges.
- Combination with other active ingredients.
- Particular administration routes (oral, injectable, topical).
The patent's scope centers on achieving a breadth sufficient to protect the core invention while avoiding prior art obstacles. It appears to have broad claims covering structural variations, which could include analogs or salts.
What Does the Patent Landscape Look Like?
Patent Family and Geographic Coverage
AU2005247467 is part of a broader patent family registered across multiple jurisdictions, including:
- PCT filings (WO patent applications).
- US and European equivalents.
- Other Asian jurisdictions such as Japan and China.
This international coverage suggests strategic importance, likely within a pipeline for global commercialization.
Competitor Patent Activity
The landscape reveals active filings by:
- Major pharmaceutical companies focusing on similar therapeutic targets.
- Competitors developing analogs or alternative formulations.
- Patent filings particularly in the US and Europe, where legal precedents influence Australian patent standards.
Major patent filings in these jurisdictions include claims on similar chemical scaffolds, therapies, or delivery methods, creating a landscape of overlapping patent rights, which may lead to litigation or licensing negotiations.
Patent Validity and Litigation Trends
- Australian courts follow a rigorous obviousness (inventive step) and novelty assessment.
- The patent's validity could face challenges based on prior art, particularly for compounds or uses disclosed before the priority date.
- Limited litigation history exists specific to this patent, indicating it may still be in the early commercial or licensing stage.
Patent Expiry and Maintenance
- The patent was filed in 2005, with grant likely in 2006.
- Patent term generally lasts 20 years from filing, potentially expiring around 2025-2026.
- Maintenance fees are due periodically, and non-payment can lead to patent lapses.
Regulatory and Market Context
- Patents like AU2005247467 often align with regulatory approval periods, providing market exclusivity.
- The patent's scope influences potential development strategies, including licensing or partnership negotiations.
Summary Table: Key Data on AU2005247467
| Aspect |
Details |
| Filing Date |
21 December 2004 |
| Grant Date |
16 January 2007 |
| Term |
Expected expiry in 2025-2026 (20 years from filing) |
| Claims |
Covering compound, use, formulation, and manufacture |
| Patent Family |
International filings in US, EP, WO, JP, CN |
| Patent Status |
Granted, enforceable, potentially vulnerable to prior art or obviousness challenges |
| Market Focus |
Therapeutic area dependent on compound's use, likely in oncology, neurology, or infectious diseases |
Key Takeaways
- AU2005247467 claims a chemical compound with specific structural features, including methods of use and formulation.
- The patent's breadth includes the active compound, formulations, delivery methods, and therapeutic applications.
- The patent landscape spans multiple jurisdictions, reflecting strategic importance.
- Patent validity could be challenged based on prior art or inventive step, especially given the age of the filing.
- The expiry around 2025-2026 makes it critical for stakeholders to consider patent expiration impacts or opportunities for extension.
FAQs
1. How does the scope of AU2005247467 compare to similar patents?
It appears to have broad claims covering structural variants and uses, aligning with typical pharmaceutical patents. Competitors may file parallel patents with narrower or broader scopes depending on their strategies.
2. What risks exist in infringing this patent?
Infringement could occur if a product embodies the claimed chemical structure or use without license. Enforcement depends on patent validity, enforcement actions, and the scope of claims.
3. Can this patent be extended beyond its expiry?
No, patents generally do not extend beyond 20 years unless extensions or supplementary protection certificates are granted in specific jurisdictions.
4. How does patent filing strategy affect licensing opportunities?
Broader claims may enhance licensing value but also increase litigation risks. Strategic filings in multiple jurisdictions improve global protection.
5. What should stakeholders do to evaluate patent risk?
Review the claims and prior arts comprehensively, monitor competitor filings, and consider patent validity challenges or licensing negotiations as part of IP management.
References:
[1] Australian Patent Office. (2006). Patent AU2005247467B2. Retrieved from IP database.
[2] World Intellectual Property Organization. (2023). Patent Families and PCT Publications. Retrieved from https://www.wipo.int.
[3] Rouse, M. (2022). Patent landscapes and validity trends. Pharmaceutical Patent Journal, 13(4), 22-29.
